
==== Front
Sao Paulo Med J
Sao Paulo Med J
Sao Paulo Med J
São Paulo Medical Journal
1516-3180
1806-9460
Associação Paulista de Medicina - APM

18094890
10.1590/S1516-31802007000500001
Editorial
Drug-eluting stent in diabetes
de Lemos Hernani Pinto Júnior *
Atallah Álvaro Nagib *
Gomes Walter José *
02 9 2007
2007
125 5 259260
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons license.
==== Body
pmcLong-term evaluation of cardiovascular risk among diabetic patients has shown that the incidence of death due to myocardial infarction among these patients is 20%, whereas among nondiabetic patients it is only 3.5%. Such observations haveled to classifying diabetes as a risk that is equivalent to established coronary artery disease.1 Among patients with established coronary artery disease, the presence of diabetes has been found to increase the five-year mortality rate to more than twice what is seen for nondiabetic patients.2 The long-term outcome for patients with diabetes following revascularization is also adverse. Increased postprocedure mortality among angioplasty patients with diabetes has been documented (3.2% versus 0.5%).3 Diabetes also confers a worse long-term outcome among patients undergoing bypass surgery. The Society of Thoracic Surgeons’ database shows that the surgical risk for diabetic patients is greater than for nondiabetic patients: 3.7% versus 2.7%, with greater risk for those requiring insulin.4

Diabetes gives rise to a number of metabolic disturbances that result in progression of atherosclerosis and occurrence of cardiac events. The presence of hyperglycemia, abnormal lipid metabolism and insulin resistance, together with occurrences of hypertension, all result in acceleration of the atherosclerotic process. Increased oxidative stress results from decreased nitric oxide production, which is caused by altered endothelial cell function due to hyperglycemia.5 Release of free fatty acids from adipose tissue due to insulin resistance leads to oxidative stress and decreased nitric oxide production.6 Increased endothelin production in diabetic patients also results in vasoconstriction. Platelet function is also altered in diabetes cases.7 Lipid abnormalities may result in elevated triglyceride levels with decreased high density lipoprotein (HDL) levels.8 Hypertension may be associated with diabetes and renal dysfunction. Rapid progression of atherosclerosis and a greater tendency towards unstable platelets result in cardiac events.

Whenever a promising study does not produce the intended solution, there is a tendency towards focusing it on a subgroup of more fragile patients, who are therefore more likely to respond well to the treatment in question. This happens particularly with studies on diabetes because of the destructive power of this disease in relation to vascular capability. Whereas physiopathological reasoning is elegant, its verification is shaky. Thus, despite many studies of high methodological quality looking for the best evidence regarding the effectiveness of drug-eluting stents in coronary diseases among subgroups of diabetic patients,9–26 there have not been any data from randomized controlled trials that could be used in meta-analyses. This seems to us to be a deliberate omission of data without statistical significance, although some studies make reference to diabetes in their presentations of results. On the other hand, these trials have frequently presented separate comments referring to diabetic patients.

A recently published systematic review27 compared drug-eluting stents and bare-metal stents, and additionally compared sirolimus-eluting stents versus paclitaxel-eluting stents. Five aims were defined for the study, and stent type in relation to diabetes was not among these aims, even though that review cited three studies28–30 in which 100% of the patients were diabetic. The discussion in that review makes contradictory statements regarding diabetic patients, while seeming to take a position in favor of bare-metal stents.

To date, there has not been any evidence that drug-eluting stents are preferable for treating diabetic patients with coronary disease. The data omissions in the published studies make this statement clear. As can be seen from the main studies, there have not been any data supporting the effectiveness of drug-eluting stents and consequently their use as the preferential treatment for coronary disease in diabetic patients. Many revascularization results have been given without specifying whether the revascularization was surgical or percutaneous. This lack of precision in defining outcomes has caused many misleading conclusions in the medical literature in this field.

Hernani Pinto de Lemos Júnior, MD. Assistant in the Brazilian Cochrane Center and Discipline of Evidence-Based Medicine of Universidade Federal de São Paulo — Escola Paulista de Medicina (Unifesp-EPM), São Paulo, Brazil. E-mail: hernani.jr@uol.com.br

Álvaro Nagib Atallah, MD, PhD. Full professor and Head of the Discipline of Emergency Medicine and Evidence-Based Medicine of Universidade Federal de São Paulo — Escola Paulista de Medicina (Unifesp-EPM). Director of the Brazilian Cochrane Center and Scientific Director of Associação Paulista de Medicina (APM), São Paulo, Brazil. E-mail: atallahmbe@uol.com.br

Walter José Gomes, MD, PhD. Associate professor, Discipline of Cardiovascular Surgery, Universidade Federal de São Paulo – Escola Paulista de Medicina (Unifesp-EPM), São Paulo, Brazil. E-mail: wjgomes.dcir@epm.br
==== Refs
REFERENCES

1 Stein B Weintraub WS Gebhart SP Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty Circulation 1995 91 4 979 989 7850985
2 Barzilay JI Kronmal RA Bittner V Eaker E Evans C Foster ED Coronary artery disease and coronary artery bypass grafting in diabetic patients aged > or = 65 years (report from the Coronary Artery Surgery Study [CASS] Registry) Am J Cardiol 1994 74 4 334 339 8059694
3 Silva JA Escobar A Collins TJ Ramee SR White CJ Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients Circulation 1995 92 7 1731 1736 7671354
4 Moreno PR Murcia AM Palacios IF Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus Circulation 2000 102 18 2180 2184 11056089
5 Pickup JC Chusney GD Thomas SM Burt D Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes Life Sci 2000 67 3 291 300 10983873
6 Marx N Imhof A Froehlich J Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease Circulation 2003 107 15 1954 1957 12695287
7 Blüher M Unger R Rassoul F Richter V Paschke R Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes Diabetologia 2002 45 2 210 216 11935152
8 Morrison DA Sethi G Sacks J Percutaneous coronary intervention versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: The VA AWESOME multicenter registry: comparison with the randomized clinical trial J Am Coll Cardiol 2002 39 2 266 273 11788218
9 Moses JW Leon MB Popma JJ Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 2003 349 14 1315 1323 14523139
10 Schampaert E Cohen EA Schlüter M The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS) J Am Coll Cardiol 2004 43 6 1110 1115 15028375
11 Schofer J Schlüter M Gershlick AH Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) Lancet 2003 362 9390 1093 1099 14550694
12 Morice MC Serruys PW Sousa JE A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 2002 346 23 1773 1780 12050336
13 Park SJ Shim WH Ho DS A paclitaxel-eluting stent for the prevention of coronary restenosis N Engl J Med 2003 348 16 1537 1545 12700373
14 Gershlick A De Scheerder I Chevalier B Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial Circulation 2004 109 4 487 493 14744971
15 Lansky AJ Costa RA Mintz GS Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial Circulation 2004 109 16 1948 1954 15078794
16 Grube E Silber S Hauptmann KE TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions Circulation 2003 107 1 38 42 12515740
17 Colombo A Drzewiecki J Banning A Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions Circulation 2003 108 7 788 794 12900339
18 Stone GW Ellis SG Cox DA A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 2004 350 3 221 231 14724301
19 Grube E Taxus VI: 9 months results Insight into diabetics Euro PCRonline.com. Available from: http://www.europcronline.com/fo/lecture/zoom_diapo.php?id=1234&indice=2 Accessed in 2007 (Oct 23)
20 Grubeng L TAXUS VI: Paclitaxel-Eluting Stents for the Treatment of Longer Lesions – Focus on Diabetes European Congress of Cardiology 2004 Available from: http://www.medscape.com/viewarticle/489421 Accessed in 2007 (Oct 23)
21 Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators JAMA 1997 277 9 715 721 9042843
22 King SB 3rd Kosinski AS Guyton RA Lembo NJ Weintraub WS Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST) J Am Coll Cardiol 2000 35 5 1116 1121 10758949
23 Serruys PW Ong AT van Herwerden LA Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial J Am Coll Cardiol 2005 46 4 575 581 16098418
24 Zhang Z Mahoney EM Stables RH Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial Circulation 2003 108 14 1694 1700 12975252
25 Breeman A Bertrand ME Ottervanger JP Diabetes does not influence treatment decisions regarding revascularization in patients with stable coronary artery disease Diabetes Care 2006 29 9 2003 2011 16936144
26 Ben-Gal Y Moshkovitz Y Nesher N Drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus Ann Thorac Surg 2006 82 5 1692 1697 17062230
27 Stettler C Wandel S Allemann S Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 2007 370 9591 937 948 17869634
28 Sabaté M Jiménez-Quevedo P Angiolillo DJ Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetics patients: the diabetes and sirolimus-eluting stent (DIABETES) trial Circulation 2005 112 14 2175 2183 16203930
29 Chan C Zambahari R Kaul U Cohen SA Buchbinder M Outcomes in diabetics patients with multivessel disease and long lesions: results from the DECODE STUDY Am J Cardiol 2005 96 7A 31H 31H [abstract] 15979428
30 Baumgart D Klauss V Baer F 1-year results of the SCORPIUS Trial - a German multicenter investigation of the effectiveness of sirolimus-eluting stents in diabetic patients Annual Scientific Meeting of the Transcatheter Cardiovascular Therapeutics October 22-27 Washington 2006 [abstract TCT-288]. Available from: http://www.tct2006.com/pdf/Final%20Program%20Relsd.pdf Accessed in 2007 (Oct 23)
